Difference between revisions of "Bladder cancer - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Tag: New redirect
 
m (Removed redirect to Urothelial carcinoma - historical)
Tag: Removed redirect
Line 1: Line 1:
−
#REDIRECT [[Urothelial carcinoma - historical]]
+
<span id="BackToTop"></span>
 +
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
 +
[[#top|Back to Top]]
 +
</div>
 +
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Bladder cancer|main bladder cancer page]] for current regimens.
 +
{| class="wikitable" style="float:right; margin-right: 5px;"
 +
|-
 +
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
 +
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 +
|}
 +
{{TOC limit|limit=3}}
 +
 
 +
=Nonmuscle invasive bladder cancer=
 +
==Intravesicular Doxorubicin monotherapy {{#subobject:8034b6|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:49ccdb|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
! style="width: 20%" |Study
 +
! style="width: 20%" |Dates of enrollment
 +
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 +
! style="width: 20%" |Comparator
 +
! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
| rowspan="2" |[https://doi.org/10.1016/s0022-5347(17)40002-4 Martínez-Piñeiro et al. 1990]
 +
| rowspan="2" |1980-1988
 +
| rowspan="2" style="background-color:#1a9851" |Phase 3 (C)
 +
|1. [[Bladder_cancer#Bacillus_Calmette-Guérin_.28BCG.29_monotherapy|BCG]]
 +
| style="background-color:#d73027" |Inferior RFS
 +
|-
 +
|2. [[Bladder_cancer#Intravesicular_Thiotepa_monotherapy|Thiotepa]]
 +
| style="background-color:#d3d3d3" |Not reported
 +
|-
 +
|[https://doi.org/10.1056/NEJM199110243251703 Lamm et al. 1991 (SWOG 8216)]
 +
|1983-1985
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Bladder_cancer#Bacillus_Calmette-Guérin_.28BCG.29_monotherapy|BCG]]
 +
| style="background-color:#fc8d59" |Seems to have inferior DFS
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Doxorubicin (Adriamycin)]] 50 mg intravesicularly once on day 1
 +
'''7-day cycle for 5 cycles, then 30-day cycle for 11 cycles (approximately 1 year)'''
 +
</div></div>
 +
===References===
 +
#Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. [https://doi.org/10.1016/s0022-5347(17)40002-4 link to original article] '''contains partial protocol''' [https://pubmed.ncbi.nlm.nih.gov/2106041/ PubMed]
 +
#'''SWOG 8216:''' Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991 Oct 24;325(17):1205-9. [https://doi.org/10.1056/NEJM199110243251703 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/1922207/ PubMed]
 +
==Intravesicular Thiotepa monotherapy {{#subobject:5b9d6c|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:97d2e7|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
! style="width: 20%" |Study
 +
! style="width: 20%" |Dates of enrollment
 +
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 +
! style="width: 20%" |Comparator
 +
! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
| rowspan="2" |[https://doi.org/10.1016/s0022-5347(17)40002-4 Martínez-Piñeiro et al. 1990]
 +
| rowspan="2" |1980-1988
 +
| rowspan="2" style="background-color:#1a9851" |Phase 3 (C)
 +
|1. [[Bladder_cancer#Bacillus_Calmette-Guérin_.28BCG.29_monotherapy|BCG]]
 +
| style="background-color:#d73027" |Inferior RFS
 +
|-
 +
|2. [[#Intravesicular_Doxorubicin_monotherapy|Doxorubicin]]
 +
| style="background-color:#d3d3d3" |Not reported
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Thiotepa (Thioplex)]] 50 mg intravesicularly x 15 treatments
 +
</div></div>
 +
===References===
 +
#Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. [https://doi.org/10.1016/s0022-5347(17)40002-4 link to original article] '''contains partial protocol''' [https://pubmed.ncbi.nlm.nih.gov/2106041/ PubMed]
 +
[[Category:Bladder cancer regimens]]
 +
[[Category:Historical regimens]]
 +
[[Category:Disease-specific pages]]
 +
[[Category:Urothelial carcinomas]]

Revision as of 23:54, 9 September 2023

Back to Top

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main bladder cancer page for current regimens.

2 regimens on this page
2 variants on this page


Nonmuscle invasive bladder cancer

Intravesicular Doxorubicin monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Martínez-Piñeiro et al. 1990 1980-1988 Phase 3 (C) 1. BCG Inferior RFS
2. Thiotepa Not reported
Lamm et al. 1991 (SWOG 8216) 1983-1985 Phase 3 (C) BCG Seems to have inferior DFS

Chemotherapy

7-day cycle for 5 cycles, then 30-day cycle for 11 cycles (approximately 1 year)

References

  1. Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. link to original article contains partial protocol PubMed
  2. SWOG 8216: Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991 Oct 24;325(17):1205-9. link to original article contains dosing details in manuscript PubMed

Intravesicular Thiotepa monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Martínez-Piñeiro et al. 1990 1980-1988 Phase 3 (C) 1. BCG Inferior RFS
2. Doxorubicin Not reported

Chemotherapy

References

  1. Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. link to original article contains partial protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Bladder_cancer_-_historical&oldid=77642"